Moderna Management

Management criteria checks 3/4

Moderna's CEO is Stephane Bancel, appointed in Oct 2011, has a tenure of 13.58 years. total yearly compensation is $17.07M, comprised of 9.2% salary and 90.8% bonuses, including company stock and options. directly owns 5.49% of the company’s shares, worth €1.16B. The average tenure of the management team and the board of directors is 4.5 years and 10.4 years respectively.

Key information

Stephane Bancel

Chief executive officer

US$17.1m

Total compensation

CEO salary percentage	9.2%
CEO tenure	13yrs
CEO ownership	5.5%
Management average tenure	4.5yrs
Board average tenure	10.4yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Stephane Bancel's remuneration changed compared to Moderna's earnings?
Date	Total Compensation	Salary	Company Earnings
Jun 30 2024	n/a	n/a	-US$6b
Mar 31 2024	n/a	n/a	-US$6b
Dec 31 2023	US$17m	US$2m	-US$5b
Sep 30 2023	n/a	n/a	-US$3b
Jun 30 2023	n/a	n/a	US$1b
Mar 31 2023	n/a	n/a	US$5b
Dec 31 2022	US$19m	US$1m	US$8b
Sep 30 2022	n/a	n/a	US$12b
Jun 30 2022	n/a	n/a	US$14b
Mar 31 2022	n/a	n/a	US$15b
Dec 31 2021	US$18m	US$990k	US$12b
Sep 30 2021	n/a	n/a	US$7b
Jun 30 2021	n/a	n/a	US$3b
Mar 31 2021	n/a	n/a	US$598m
Dec 31 2020	US$13m	US$946k	-US$747m
Sep 30 2020	n/a	n/a	-US$597m
Jun 30 2020	n/a	n/a	-US$488m
Mar 31 2020	n/a	n/a	-US$505m
Dec 31 2019	US$9m	US$921k	-US$514m
Sep 30 2019	n/a	n/a	-US$535m
Jun 30 2019	n/a	n/a	-US$499m
Mar 31 2019	n/a	n/a	-US$459m
Dec 31 2018	US$59m	US$863k	-US$402m
Sep 30 2018	n/a	n/a	-US$299m
Jun 30 2018	n/a	n/a	-US$280m
Mar 31 2018	n/a	n/a	-US$266m
Dec 31 2017	US$7m	US$651k	-US$270m

Compensation vs Market: Stephane's total compensation ($USD17.07M) is above average for companies of similar size in the Austrian market ($USD4.39M).

Compensation vs Earnings: Stephane's compensation has been consistent with company performance over the past year.

CEO

Stephane Bancel (51 yo)

13yrs

Tenure

US$17,068,514

Compensation

Mr. Stephane Bancel serves as Board Director of Indigo Agriculture Inc since 2020. Mr Bancel serves as Interim President of Valera LLC. Mr. Bancel serves as a Special Partner at Flagship Pioneering since F...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Stephane Bancel	CEO & Director	13yrs	US$17.07m	5.49% $ 1.2b
Stephen Hoge	President	no data	US$7.34m	0.42% $ 87.7m
James Mock	Chief Financial Officer	2.1yrs	US$4.32m	0.0023% $ 480.9k
Shannon Klinger	Chief Legal Officer & Corporate Secretary	3.3yrs	US$4.31m	0.0047% $ 995.6k
Jerh Collins	Chief Technical Operations & Quality Officer	1.8yrs	no data	no data
Brad Miller	Chief Information Officer	1.8yrs	no data	no data
Lavina Talukdar	Senior VP & Head of Investor Relations	5.5yrs	no data	no data
Colleen Hussey	Senior Director of Corporate Communications	no data	no data	no data
Tracey Franklin	Chief Human Resources Officer	5yrs	no data	no data
Melanie Ivarsson	Chief Development Officer	4.8yrs	no data	no data
Dave Johnson	Chief Data & AI Officer	no data	no data	no data
Charbel Haber	Senior VP & Head of Global Regulatory Science	4.5yrs	no data	no data

4.5yrs

Average Tenure

50yo

Average Age

Experienced Management: MRNA's management team is considered experienced (4.5 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Stephane Bancel	CEO & Director	13.6yrs	US$17.07m	5.49% $ 1.2b
Noubar Afeyan	Co-Founder	14.8yrs	US$663.52k	0.58% $ 122.0m
Elizabeth Tallett	Independent Director	4.3yrs	US$481.27k	0.00018% $ 38.0k
Robert Langer	Member of Scientific Advisory Board	no data	US$461.27k	2.99% $ 631.5m
Scott Canute	Member of Technology Advisory Board	10.4yrs	no data	no data
Elizabeth Nabel	Independent Director	3.6yrs	US$476.25k	0.00055% $ 116.0k
Fred Regnier	Member of Technology Advisory Board	10.4yrs	no data	no data
Francois Nader	Independent Non Executive Director	4.8yrs	US$481.27k	0.0054% $ 1.1m
James Swartz	Member of Technology Advisory Board	10.4yrs	no data	no data
Ulrich von Andrian-Werburg	Member of Scientific Advisory Board	no data	no data	no data
Jack Szostak	Chairman of Scientific Advisory Board	10.4yrs	no data	no data
John Aunins	Member of Technology Advisory Board	10.4yrs	no data	no data

10.4yrs

Average Tenure

65yo

Average Age

Experienced Board: MRNA's board of directors are seasoned and experienced ( 10.4 years average tenure).

Moderna Management

Management criteria checks 3/4

Key information

Recent management updates

Moderna, Inc. as Abbas Hussain to Board of Directors

Moderna, Inc. Announces Board Changes

Insufficient new directors

Moderna, Inc., Annual General Meeting, May 06, 2024

CEO & Director recently sold €2.2m worth of stock

Moderna Announces Changes to Commercial Organization

Recent updates

Moderna, Inc. as Abbas Hussain to Board of Directors

Moderna Receives Health Canada Approval for Updated COVID-19 Vaccine Targeting KP.2 Variant Of SARS-COV-2 For Ages Six Months And Older

Moderna, Inc. Announces EMA Committee for Medicinal Products for Human Use Adopts Positive Opinion Recommending Authorization of Moderna's COVID-19 mRNA Vaccine Targeting the SARS-COV-2 Variant JN.1

Moderna, Inc. Receives Medicines and Healthcare Products Regulatory Agency Authorization for Updated COVID-19 Vaccine Targeting SARS-CoV-2 Variant JN.1

Taiwan Food & Drug Administration Approves Moderna, Inc.'s COVID-19 mRNA Vaccine Targeting the SARS-CoV-2 Variant JN.1

Albertsons Companies, Inc. Offers the Latest Monovalent mRNA COVID Vaccines from Pfizer and Moderna Along with the Annual Flu Vaccine

Moderna Receives European Commission Approval for RSV Vaccine Mresvia(R)

Gainey McKenna & Egleston Files Class Action Lawsuit Against Moderna Inc

Second quarter 2024 earnings released: US$3.33 loss per share (vs US$3.62 loss in 2Q 2023)

Moderna, Inc. Revises Earnings Guidance for the Year 2024

Moderna, Inc. Announces Board Changes

Moderna, Inc. to Report Q2, 2024 Results on Aug 01, 2024

Moderna, Inc Announces EMA Committee for Medicinal Products for Human Use

Moderna, Inc. Announces Positive Phase 3 Efficacy Data for mRNA-1283

Moderna, Inc Announces Positive Phase 3 Data for Combination Vaccine Against Influenza and COVID-19

Moderna Files FDA Application for the JN.1 Targeting COVID-19 Vaccine

Moderna & Merck Announces 3-Year Data for mRNA-4157 (V940) in Combination with KEYTRUDA (Pembrolizumab)

Moderna Announces Update on Investigational Rsv Vaccine

First quarter 2024 earnings released: US$3.08 loss per share (vs US$0.20 profit in 1Q 2023)

Moderna, Inc. to Report Q1, 2024 Results on May 02, 2024

Arbutus Biopharma Announces Claim Construction Ruling in Its Ongoing Patent Infringement Lawsuit Against Moderna

Insufficient new directors

Moderna, Inc. Advances Multiple Vaccine Programs to Late-Stage Clinical Trials

Moderna, Inc. Achieves Positive Interim Results from Phase 3 Trial of Next-Generation COVID-19 Vaccine

Full year 2023 earnings released: US$12.34 loss per share (vs US$21.22 profit in FY 2022)

Moderna, Inc., Annual General Meeting, May 06, 2024

CEO & Director recently sold €2.2m worth of stock

Moderna, Inc. to Report Q4, 2023 Results on Feb 22, 2024

Moderna, Inc. Reiterates Earnings Guidance for the Year 2024, 2025 and 2026

Moderna Announces Changes to Commercial Organization

Moderna Announces Changes to Commercial Organization

Moderna, Inc. Provides Sales Guidance for the Year 2023

Third quarter 2023 earnings released: US$9.53 loss per share (vs US$2.67 profit in 3Q 2022)

Moderna Announces First Participant Dosed in Phase 3 Study of mRNA-1083, a Combination Vaccine against Influenza and COVID-19

Investor sentiment deteriorates as stock falls 16%

Moderna, Inc. to Report Q3, 2023 Results on Nov 02, 2023

Moderna, Inc. Announces Positive Phase 1/2 Data from mRNA-1083, the company's Combination Vaccine Against Influenza and COVID-19

Moderna, Inc. Announces Ema Committee for Medicinal Products for Human Use Adopts Positive Opinion Recommending Authorization of Moderna's Updated Covid-19 Vaccine in the European Union

Moderna Receives U.S. FDA Approval for Updated Covid-19 Vaccine

Moderna Clinical Trial Data Confirm Its Updated Covid-19 Vaccine Generates Strong Immune Response in Humans Against Ba.2.86

New major risk - Revenue and earnings growth

Investor sentiment improves as stock rises 19%

Moderna Clinical Trial Data Confirm its Updated COVID-19 Vaccine Generates Robust Immune Response in Humans Against Widely Circulating Variants

UMass Chan Medical School Announces Enrollment in Study to Explore Impact of Cytomegalovirus (CMV) Transmission in Early Education Settings

Moderna, Inc. Provides Sales Guidance for the Full Year 2023

Second quarter 2023 earnings released: US$3.62 loss per share (vs US$5.55 profit in 2Q 2022)

CEO Compensation Analysis

CEO

Tenure

Compensation

Leadership Team

Average Tenure

Average Age

Board Members

Average Tenure

Average Age